MedTrace Logo

Radio-opaque Contrast Agents for Liver Cancer Targeting With KIM During Radiation Therapy

NCT05169177 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2026-05-19

No results posted yet for this study

Summary

This observational study will investigate the properties of image files standardly collected during radiation therapy treatment in a cross-section of liver cancer patients who received stereotactic ablative body radiation therapy (SABR) after trans-catheter arterial chemo emobilisation (TACE). Specifically, it will determine whether the radio-opaque contrast agents in the image files can be detected by tumour-tracking software (KIM).

Conditions

  • Liver Neoplasm

Sponsors & Collaborators

  • Calvary Mater Newcastle, Australia

    collaborator OTHER

  • Western Sydney Local Health District

    collaborator OTHER

  • Austin Health

    collaborator OTHER_GOV

  • Peter MacCallum Cancer Centre, Australia

    collaborator OTHER

  • Princess Alexandra Hospital, Brisbane, Australia

    collaborator OTHER

  • University of Sydney

    lead OTHER

Principal Investigators

  • Paul Keall, PhD · University of Sydney

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-17
Primary Completion
2026-10-31
Completion
2026-10-31

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05169177 on ClinicalTrials.gov